Shattuck Labs, Inc.
Shattuck Labs, Inc.
Your view on STTK
Overview
What the company does, where it operates, and who runs it.
About Shattuck Labs, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Taylor H. Schreiber
- Headquarters
- 500 West 5th Street, Austin, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Taylor H. Schreiber
- Headquarters
- 500 West 5th Street, Austin, TX, US
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Shattuck Labs, Inc., and the rating behind it. STTK last traded at $6.20; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Shattuck Labs, Inc.. Starting points for Shattuck Labs, Inc.: EPS -$0.41, beta 1.10 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Shattuck Labs, Inc.. Shattuck Labs, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Shattuck Labs, Inc.. Trailing twelve-month EPS for Shattuck Labs, Inc. stands at -$0.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Shattuck Labs, Inc.. Shattuck Labs, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Shattuck Labs, Inc. valued side by side against its closest peers. Shattuck Labs, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Shattuck Labs, Inc., and how their positions are changing. At a $560.3M market value, institutional positions materially move Shattuck Labs, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Shattuck Labs, Inc. executives and directors. Shares of Shattuck Labs, Inc. have traded between $0.69 and $2.71 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Shattuck Labs, Inc.. Shattuck Labs, Inc. is a $560.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Shattuck Labs, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Shattuck Labs, Inc.. Coverage tracks Shattuck Labs, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.